In the absence of a clinical history of cognitive decline or dementia, our previous screening protocols incorporated p-tau immunostaining of the hippocampus only, principally to assess for the presence of Alzheimer disease neuropathologic change (ADNC). The gene discussed is MAPT; the disease is dementia.